(2021) (166) reported delayed tumor growth in low STn expressing tumors when treated with the dual STn- and CD47-specific CAR-T cells, but not after therapy with the single anti-STn CAR-T cells in an in vivo ovarian cancer model. This evidence concerns the gene CD47 and ovarian carcinoma.